Back

Targeting mutant TNNT2-induced epigenetic perturbation and pathogenic signaling in left ventricular non-compaction cardiomyopathy

Li, Y.-Y.; Tseng, W.-C.; Kao, H.-L.; Shie, Y.-S.; Chiu, S.-N.; Wu, Y.-T.; Sun, C.-M.; Tzeng, S.-R.; Lai, L.-C.; Lin, M.-H.; Wu, Y.-W.; Ko, K.-Y.; Juang, J.-M. J.; Hsieh, R.; Wu, M.-H.; Chen, W.-P.; Ho, H.-N.

2024-10-11 cardiovascular medicine
10.1101/2024.10.09.24314670 medRxiv
Show abstract

BackgroundCompound mutations of TNNT2R141W/+ (encoding troponin T) and MYPNS1296T/+ (encoding myopalladin) are associated with familial left ventricle non-compaction cardiomyopathy (LVNC). However, it remains unclear in which would be the pathogenic mutation, the underlying mechanism, and the target therapy for LVNC. MethodsKnock-in C57BL/6J mice harboring mutations in orthologous genes in Tnnt2R154W or/and MypnS1291T and human cardiomyocytes derived from iPSC of healthy donors and LVNC patients (LVNC-hCM) were employed for disease modeling, omics analysis, mechanistic study, and drug development. ResultsUsing knock-in mice for disease modeling, it was clarified that the orthologous mutation in Tnnt2, but not in Mypn, led to cardiac hypertrabeculation, noncompaction, and heart failure. 3D protein structure modeling by Swiss-model found a loss of slat bridge between TNNT2(R141W) and E-257 in tropomyosin, contributing to the decreased cardiac contraction. Further mechanistic study discovered that troponin T (TNNT2) appears to function as an HDAC1 sponge in cardiomyocyte nuclei. The compromised association between nuclear TNNT2(R141W) and HDAC1 causes cardiac epigenetic perturbation and subsequentially leads to transcriptional dysregulation. The downregulation of cardiac muscular genes was concomitant with the impairment of cardiac contraction, which would be partially rescued by pan HDAC inhibitor. Besides, the upregulation of TGF{beta}-signaling molecules and EZH2 did contribute to cardiac growth defects, which were mitigated by TGF{beta}R1 inhibitor (A83-01) and EZH2 inhibitor (GSK503), respectively. Simvastatin, a hit drug identified from the repurposed drug screening, can restore nuclear TNNT2(R141W)-HDAC1 association, thereby recovering cardiac epigenetic, translational profiles, growth and function in LVNC-hCM in vitro and cardiac function in LVNC mice harboring Tnnt2R154W in vivo. The cardiac function was significantly improved in the proband receiving 5 mg once daily for consecutive two years. ConclusionMutant TNNT2(R141W) diminished its nuclear HDAC1 sponge function in cardiomyocyte to induce LVNC pathogenesis through perturbating cardiac epigenetic and the gene expressions. Targeting to HDAC, TGF{beta}, EZH2 may rescue part of cardiac pathological signaling. Simvastatin can act as a chemical chaperone to comprehensively recover cardiac epigenetic via restoring nuclear TNNT2(R141W)-HDAC1 association.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Frontiers in Cardiovascular Medicine
49 papers in training set
Top 0.1%
28.1%
2
BMC Cardiovascular Disorders
14 papers in training set
Top 0.1%
12.7%
3
Journal of the American Heart Association
119 papers in training set
Top 2%
4.4%
4
European Journal of Pharmacology
11 papers in training set
Top 0.1%
4.4%
5
PLOS ONE
4510 papers in training set
Top 38%
3.6%
50% of probability mass above
6
The American Journal of Cardiology
15 papers in training set
Top 0.7%
2.6%
7
Medicine
30 papers in training set
Top 0.7%
2.6%
8
Frontiers in Pharmacology
100 papers in training set
Top 1%
2.1%
9
Biomedicines
66 papers in training set
Top 0.9%
1.7%
10
Frontiers in Medicine
113 papers in training set
Top 4%
1.7%
11
International Journal of Cardiology
13 papers in training set
Top 0.3%
1.7%
12
Circulation: Heart Failure
14 papers in training set
Top 0.3%
1.5%
13
International Journal of Molecular Sciences
453 papers in training set
Top 9%
1.5%
14
Journal of Molecular and Cellular Cardiology
39 papers in training set
Top 0.5%
1.5%
15
Heart Rhythm
22 papers in training set
Top 0.4%
1.5%
16
Science Bulletin
22 papers in training set
Top 0.4%
1.4%
17
Scientific Reports
3102 papers in training set
Top 64%
1.4%
18
European Journal of Preventive Cardiology
13 papers in training set
Top 0.6%
1.4%
19
Atherosclerosis
29 papers in training set
Top 0.9%
1.2%
20
Frontiers in Cellular and Infection Microbiology
98 papers in training set
Top 4%
1.2%
21
eLife
5422 papers in training set
Top 50%
1.1%
22
Journal of Translational Medicine
46 papers in training set
Top 2%
1.0%
23
Frontiers in Neurology
91 papers in training set
Top 4%
0.9%
24
European Heart Journal
16 papers in training set
Top 0.7%
0.9%
25
Journal of Advanced Research
15 papers in training set
Top 0.5%
0.9%
26
BMC Medicine
163 papers in training set
Top 7%
0.8%
27
Open Heart
19 papers in training set
Top 1%
0.8%
28
Pharmacological Research
15 papers in training set
Top 0.3%
0.7%
29
Frontiers in Physiology
93 papers in training set
Top 6%
0.7%
30
Computers in Biology and Medicine
120 papers in training set
Top 5%
0.7%